Dr. Burtness on Promise of Frontline Pembrolizumab in Metastatic HNSCC
March 30th 2019
Barbara Burtness, MD, professor of Medicine (Medical Oncology); Disease Aligned Research Team Leader, Head and Neck Cancers Program; co-director, Developmental Therapeutics Research Program; of Yale Cancer Center, discusses the promise of frontline pembrolizumab in the treatment of patients with metastatic head and neck squamous cell carcinoma.